Viewing Study NCT06614751

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:49 PM
Ignite Modification Date: 2026-03-13 @ 12:44 PM
Study NCT ID: NCT06614751
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-09-27
First Post: 2024-09-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Sponsor: Danatlas Pharmaceuticals Co., Ltd
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Cancers View
None BRCA Mutation View
None HRD Cancer View
None Breast Cancer View
None Prostate Cancer View
None Colorectal Cancer View
None Pancreatic Cancer View
None Endometrial Cancer View
None Gastric Cancer View
None Advanced Cancer View
None Metastatic Solid Tumors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PARGi View
None DAT-2645 View
None PARPi View
None Advanced solid tumors View
None Metastatic solid tumors View
None HRD gene alteration View
None Homologous recombination View
None BRCA View
None BRCA1/2 View
None PALB2 View
None RAD51C View
None RAD51D View